WO2016105084A3 - 당뇨병 치료용 약제학적 조성물 - Google Patents

당뇨병 치료용 약제학적 조성물 Download PDF

Info

Publication number
WO2016105084A3
WO2016105084A3 PCT/KR2015/014096 KR2015014096W WO2016105084A3 WO 2016105084 A3 WO2016105084 A3 WO 2016105084A3 KR 2015014096 W KR2015014096 W KR 2015014096W WO 2016105084 A3 WO2016105084 A3 WO 2016105084A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
treating diabetes
dpp
inhibitor
metformin
Prior art date
Application number
PCT/KR2015/014096
Other languages
English (en)
French (fr)
Other versions
WO2016105084A2 (ko
Inventor
홍언표
김동욱
홍혜숙
배진건
Original Assignee
주식회사 한독
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53500898&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016105084(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 주식회사 한독 filed Critical 주식회사 한독
Priority to MYPI2017702340A priority Critical patent/MY196438A/en
Priority to CN201580070627.7A priority patent/CN107205969B/zh
Priority to SG11201705194XA priority patent/SG11201705194XA/en
Publication of WO2016105084A2 publication Critical patent/WO2016105084A2/ko
Publication of WO2016105084A3 publication Critical patent/WO2016105084A3/ko
Priority to PH12017501184A priority patent/PH12017501184B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 메트포르민(metformin)과 DPP-IV 억제제를 포함하는 당뇨병 치료용 약제학적 조성물에 관한 것이다. 본 발명에 따른 당뇨병 치료용 약제학적 조성물은 DPP-IV 억제제와 메트포르민 사이의 접촉을 차단할 수 있으므로, 유효기간이 증가하며 조성물 내에 존재하는 유연물질의 종류뿐만 아니라 그 양도 감소하는 장점이 있다. 더불어, DPP-IV 억제제의 신속한 방출이 가능하면서도 메트포르민의 서방형 방출을 조절할 수 있는 장점이 있다.
PCT/KR2015/014096 2014-12-23 2015-12-22 당뇨병 치료용 약제학적 조성물 WO2016105084A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MYPI2017702340A MY196438A (en) 2014-12-23 2015-12-22 Pharmaceutical Composition for Treating Diabetes
CN201580070627.7A CN107205969B (zh) 2014-12-23 2015-12-22 糖尿病治疗用药物组合物
SG11201705194XA SG11201705194XA (en) 2014-12-23 2015-12-22 Pharmaceutical composition for treating diabetes
PH12017501184A PH12017501184B1 (en) 2014-12-23 2017-06-22 Pharmaceutical composition for treating diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0186677 2014-12-23
KR1020140186677A KR101526825B1 (ko) 2014-12-23 2014-12-23 당뇨병 치료용 약제학적 조성물

Publications (2)

Publication Number Publication Date
WO2016105084A2 WO2016105084A2 (ko) 2016-06-30
WO2016105084A3 true WO2016105084A3 (ko) 2016-09-09

Family

ID=53500898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/014096 WO2016105084A2 (ko) 2014-12-23 2015-12-22 당뇨병 치료용 약제학적 조성물

Country Status (7)

Country Link
KR (1) KR101526825B1 (ko)
CN (1) CN107205969B (ko)
MY (1) MY196438A (ko)
PH (1) PH12017501184B1 (ko)
SG (1) SG11201705194XA (ko)
TW (1) TW201628602A (ko)
WO (1) WO2016105084A2 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106421794A (zh) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法
WO2019066359A2 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
KR102500835B1 (ko) * 2017-10-24 2023-02-17 한미약품 주식회사 리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법
TR201721824A2 (tr) * 2017-12-26 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon
CN113116850B (zh) * 2019-12-31 2024-03-19 广州玻思韬控释药业有限公司 胃滞留片
KR20230051096A (ko) * 2021-10-08 2023-04-17 (주)셀트리온 안정성이 개선된 당뇨병 치료용 약학 조성물
CN115715768A (zh) * 2022-11-24 2023-02-28 浙江昂利泰制药有限公司 一种小型西格列汀-二甲双胍缓释片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100705210B1 (ko) * 2004-09-23 2007-04-06 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
KR20140018832A (ko) * 2010-07-09 2014-02-13 비에이치브이 파르마, 인크. 레모글리플로진을 포함하는 짧은 반감기 약제용의 즉시/지연 조합 방출 전달 시스템
KR20140052970A (ko) * 2011-03-07 2014-05-07 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 및 dpp-4 억제제 또는 sglt-2 억제제를 포함하는 약제학적 조성물
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
KR20130103631A (ko) * 2005-06-03 2013-09-23 미쓰비시 타나베 파마 코퍼레이션 의약의 병용 및 그 용도
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
CN101168060B (zh) * 2007-10-12 2012-06-13 重庆医药工业研究院有限责任公司 一种含双胍和磺酰脲的稳定的药物组合物及其制备方法
CN101168059A (zh) * 2007-10-12 2008-04-30 重庆医药工业研究院有限责任公司 一种含有双胍、磺酰脲和噻唑烷二酮的稳定的药物组合物及其制备方法
CN101932241A (zh) * 2008-02-05 2010-12-29 默沙东公司 二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
CN106177958A (zh) * 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN103285398B (zh) * 2013-06-28 2015-07-22 青岛黄海制药有限责任公司 含有dpp-ⅳ抑制剂和第二种糖尿病药物的复方制剂及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100705210B1 (ko) * 2004-09-23 2007-04-06 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR20140018832A (ko) * 2010-07-09 2014-02-13 비에이치브이 파르마, 인크. 레모글리플로진을 포함하는 짧은 반감기 약제용의 즉시/지연 조합 방출 전달 시스템
KR20140052970A (ko) * 2011-03-07 2014-05-07 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 및 dpp-4 억제제 또는 sglt-2 억제제를 포함하는 약제학적 조성물
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제

Also Published As

Publication number Publication date
KR101526825B1 (ko) 2015-06-08
PH12017501184A1 (en) 2017-12-18
CN107205969B (zh) 2020-06-30
CN107205969A (zh) 2017-09-26
PH12017501184B1 (en) 2017-12-18
WO2016105084A2 (ko) 2016-06-30
TW201628602A (zh) 2016-08-16
MY196438A (en) 2023-04-11
SG11201705194XA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
WO2016105084A3 (ko) 당뇨병 치료용 약제학적 조성물
HK1254756A1 (zh) 作為組蛋白脫乙酰酶6抑制劑的1，3，4-噁二唑衍生物化合物及包含其的藥物組合物
HK1251571A1 (zh) 作為組蛋白脫乙酰基酶6抑制劑的1，3，4-噁二唑磺酰胺衍生化合物及含有其的醫藥組合物
HK1251549A1 (zh) 作為組蛋白去乙酰酶6抑制劑的1，3，4-噁二唑磺酰胺衍生物及含其的醫藥組合物
EP3438076C0 (en) USE OF A TYPE OF COMPOUNDS AS ENERGETIC MATERIAL
GB201512314D0 (en) Use of a composition containing 1,3-propanediol as an e-liquid
ZA201800015B (en) Material for enhancing attributes of a topical or surface treatment composition
HK1256042A1 (zh) 用於治療糖尿病周圍神經病變的hdac抑制劑
MX2017000487A (es) Procedimiento de secado.
PH12017501082A1 (en) Calcium carbonate for plant protection
MX2018003707A (es) Producto de superficie solida y su proceso de fabricacion.
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
MX369661B (es) Microcapsulas biocidas.
MX2021003830A (es) Uso terapéutico del glucagón y combinación que incluye el mismo.
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
WO2015149656A8 (zh) 一类2,2'-串联双噻唑类化合物及其制备方法和用途
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
EP3097918A4 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
EP3366292A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY CONTAINING ALPHA-LIPOIC ACID AND N-ACETYLCYSTEINE AS ACTIVE SUBSTANCES
WO2016038040A3 (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation
EP3165543A4 (en) Diacrylate compound, composition thereof, and cured product thereof
EP3121167A4 (en) Compound binding to pparg but not acting as promoter and pharmaceutical composition for treating pparg-related diseases containing same as active ingredient
EP3768274A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF CONDITIONS CAUSED BY CALCIUM DEFICIENCY
MX2019010723A (es) Material adsorbente y de envasado.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15873611

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12017501184

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11201705194X

Country of ref document: SG

122 Ep: pct application non-entry in european phase

Ref document number: 15873611

Country of ref document: EP

Kind code of ref document: A2